Bridging the Gap Between Explanatory and Pragmatic Trials in Inflammatory Bowel Disease

This publication has 15 references indexed in Scilit:

• Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges
  Clinical Gastroenterology and Hepatology, 2024
• Navigating the complexities of drug development for inflammatory bowel disease
  Nature Reviews Drug Discovery, 2024
• Vedolizumab for the Treatment of Chronic Pouchitis
  New England Journal of Medicine, 2023
• Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
  The Lancet, 2023
• Underrepresentation of Minorities and Underreporting of Race and Ethnicity in Crohn’s Disease Clinical Trials
  Gastroenterology, 2022
• Challenges and Opportunities in IBD Clinical Trial Design
  Gastroenterology, 2021
• The Magic of Randomization versus the Myth of Real-World Evidence
  New England Journal of Medicine, 2020
• Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn’s Disease
  Gastroenterology, 2019
• The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis
  Gastroenterology, 2013
• Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
  Clinical Gastroenterology and Hepatology, 2012